EP1208199A2 - ADN CODANT POUR LA $g(b)-TUBULINE ET LEUR UTILISATION - Google Patents

ADN CODANT POUR LA $g(b)-TUBULINE ET LEUR UTILISATION

Info

Publication number
EP1208199A2
EP1208199A2 EP00956159A EP00956159A EP1208199A2 EP 1208199 A2 EP1208199 A2 EP 1208199A2 EP 00956159 A EP00956159 A EP 00956159A EP 00956159 A EP00956159 A EP 00956159A EP 1208199 A2 EP1208199 A2 EP 1208199A2
Authority
EP
European Patent Office
Prior art keywords
dna
seq
tubulin
amino acid
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00956159A
Other languages
German (de)
English (en)
Inventor
Georg Von Samson-Himmelstjerna
Achim Harder
Thomas Schnieder
Michaela Pape
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP1208199A2 publication Critical patent/EP1208199A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to DNA coding for ß-tubulin from nematodes of the Strongylidae family, the polypeptide encoded by this DNA, the use of DNA for the diagnosis of anthelmintic resistance of these nematodes and for the identification of the species of these nematodes, the use of ß-tubulin as part of a vaccine and a method for identifying new anthelmintic or antibiotic compounds.
  • helminths Parasitic helminths (worms) pose a health problem for humans and animals and cause significant economic damage.
  • the most important anthelmintics that are currently used can be divided into three groups according to their mechanism of action:
  • the cyclic amidines pyrantel and morantel act together with the imidazothiazoles tetramisole and levamisole as cholinergic compounds for the parasitic nervous system.
  • the benzimidazoles are inhibitors of the polymerization of microtubules and lead to the degradation of tubulin, followed by the loss of several cell functions such as transport within cells and cell division.
  • the macrocyclic lactones bind and open glutaminergic chloride
  • Microtubules are made up of tubulin subunits.
  • Tubulin is a dimeric protein that consists of ⁇ - and ß-tubulin and is in a dynamic equilibrium between tubulin and microtubules. This balance can go through exogenous substances are influenced, which are called microtubule inhibitors.
  • Some of these inhibitors, such as the benzimidazoles act by binding to tubulin, preventing self-association of these subunits with growing microtubules, while at the opposite end, microtubule dissociation continues. This leads to malfunctions in vital processes within the cell and ultimately to the death of the cell and the entire organism (Lacey, E. (1990) Mode of action of benzimidazoles. Parasitology Today 6, 112-115).
  • Such microtubule inhibitors include various classes of compounds that are synthetically produced or produced by different organisms.
  • the binding of microtubule inhibitors to tubulin from different organisms shows great differences in the affinity of the binding.
  • the anthelmintics oxfendazole and thiabendazole show a high affinity for tubulin from Ascaridia galli and a low affinity for tubulin from mammals like that
  • LDA Low-density bacterium senor fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal senor fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fungal fung
  • EHA egg hatch assay
  • Codon 200 of the ß-tubulin isotype 1 gene (Elard et al. (1999) PCR diagnosis of benz- imidazole - susceptibility or - resistance in natural populations of the small ruminant parasite, Teladorsagia circumcincta, Veterinary Parasitology 80, 231-237).
  • the point mutations in codon 200 result in an amino acid exchange from phenylalanine to tyrosine and correlate with a benzimidazole resistance of the mutated protein (Kwa et al. (1995) ß-tubulin genes from parasitic nematode
  • Haemonchus contortus modulate drug resistance in Caenorhabditis elegans, Journal of Molecular Biology 246, 500-510).
  • Benzimidazoles have been described in various countries, including also in Germany (Burger, H.-J. and Bauer, C. (1987) Efficacy of four anthelmintics against benzimidazole - resistant cyathostomes of horses, Veterinary Record 120, 293-296).
  • the nucleic acid sequencing of ⁇ -tubulin cDNAs from the species of small strongyles according to the invention had an identity of over 95%.
  • identity with the known ß-tubulin sequences of sheep parasites mentioned above is only 75.4-82.6%.
  • the deduced amino acid sequences are very similar within the sequences according to the invention. This also applies to the derived ß-tubulin amino acid sequences of the sheep parasites. The identity is between 95 and 99.8%. There are very few positions at which an amino acid exchange occurs. Of particular note here is codon 200, in which a change from phenylalanine to
  • Tyrosine results results.
  • the previously published non-coding ß-tubulin sequences from different helminth species do not show any significant identity. It is therefore surprising that not only the coding sequences, but also parts of the non-coding sequences of the different species of small strongyles of the present application have a high identity. These regions are therefore also suitable for differentiating different species of small strongyles and other nematode species. PCR primers derived from these intron regions can make the specific detection smaller
  • ⁇ -tubulin from nematodes or parts thereof are known to have a protective, immunological potential (Bughio et al. (1993) Characterization and biological activities of an ⁇ -Brugia pahangi tubulin monoclonal antibodies, International Journal for Parasitology, 7, 913-924 ).
  • the ß-tubulin of the small strongyles encoded by the above-mentioned DNA can be used as a vaccine as well as monoclonal antibodies against the ß-tubulin.
  • Inhibitors of the interaction of tubulin or its subunits are important lead structures of a number of therapeutic agents which are directed against human, animal or plant diseases.
  • the importance of tubulin as a target for these compounds is far-reaching and underscores its potential for the search for new active substances to combat these diseases.
  • the invention relates to that for the ß-tubulin from nematodes of the family of
  • the ß-tubulin DNA can be genomic DNA or cDNA.
  • the DNA sequences which are the subject of this invention can be used as new members of the tubulin gene family of parasitic nematodes of the order Strongyhda, especially the subfamily of the Cyathostominae, are loaded.
  • the invention relates particularly to the DNA sequences which code for ⁇ -tubulin from parasitic nematodes of the genera Cyathostomum and Cylicocycle.
  • the invention also relates to DNA sequences which form one for one of the amino acid sequences according to SEQ LD NO. 2, 4, 6, 8 or 10 coding polynucleotide have an identity of more than 85%.
  • the invention likewise preferably relates to DNA sequences which form one for one of the amino acid sequences according to SEQ LD NO. 2, 4, 6, 8 or 10 coding polynucleotide have an identity of more than 95%.
  • the invention relates in particular to DNA coding for ⁇ -tubulin.
  • Sequences that come from parasitic nematodes of the genera Cylicocycle and Cyathostomum very particularly those sequences that come from parasitic nematodes of the species Cylicocyclus nassatus, preferably DNA according to SEQ ID NO. 3, 5, 7, 9 or 11 or from Cyathosto um coronatum, preferably DNA according to SEQ JD NO. 1.
  • the invention also relates to DNA sequences as described above which, in contrast to these sequences in codon 200, have at least one point mutation or one nucleotide exchange. These point mutations result in a change in the amino acid sequence encoded by this DNA, e.g. B. one
  • the invention also relates to DNA sequences which are complementary to the DNA or fragments of this DNA described above, and fragments of these DNA sequences.
  • DNA sequences or fragments Oligonucleotides derived from one of the abovementioned or under SEQ ID NO. 1, 3, 5, 7, 9 or 11 described DNA sequences are derived or are derived from 85% identical, preferably 95% identical sequences and complementary strands and can hybridize to them.
  • the invention preferably relates to oligonucleotides consisting of or comprising one of the sequences according to SEQ LD NO. 12 to SEQ ID NO. 51, which hybridize to the above-mentioned DNA sequences, preferably in the region of non-coding sequence segments of the ⁇ -tubulin genes.
  • the invention also preferably relates to oligonucleotides consisting of or comprising one of the sequences according to SEQ ID NO. 12 to SEQ ID NO. 51 that hybridize to coding regions of the above sequences.
  • the invention also relates to RNA sequences which are complementary to the DNA or fragments of this DNA described above, and fragments of these RNA sequences.
  • These RNA sequences or these fragments comprise ribooligonucleotides which correspond to a region of one of the abovementioned or under SEQ ID NO. 1, 3, 5, 7, 9 or 11 described DNA sequences, complementary sequences or 85%, preferably 95% identical DNA sequences and can hybridize to these.
  • the invention also relates to an expression construct, which comprises one of the DNA sequences described above, and a DNA sequence linked to it, which enables the expression of the DNA.
  • These include, for example, at least one promoter for constitutive or inducible expression or enhancers.
  • Suitable promoters for expression in E. coli are natural hybrid or bacteriophage promoters, preferably promoters from the group of ⁇ phages, hsp, omp or synthetic promoters such as, for example, in WO 98/5625, DE 3 430 683 or EP 0 173 149 called.
  • the invention also relates to vectors which comprise one of the DNA sequences described above and which allow expression of the ⁇ -tubulin according to the invention or fragments thereof in a host cell.
  • the invention also relates to host cells which contain the abovementioned DNA, an expression construct as mentioned above, or a vector and the expression of the ⁇ -tubulin or fragments thereof.
  • the invention also relates to polypeptides which are encoded by one of the above-mentioned DNA sequences or fragments of these DNA sequences, and fragments of these polypeptides.
  • the invention preferably relates to polypeptides which are derived from a DNA sequence comprising SEQ ID NO. 1, 3, 5, 7, 9 or 11 are encoded, of DNA sequences which have an identity of 85%, preferably 95%, of these sequences, or of fragments of this DNA.
  • This invention also relates to polypeptides which are encoded by a DNA sequence described above and which contain at least one point mutation in codon 200 as described above and show resistance to benzimidazoles, and fragments of these polypeptides.
  • the invention very particularly preferably relates to polypeptides comprising one of those in SEQ ID NO. 2, 4, 6, 8 or 10 described amino acid sequences or fragments thereof.
  • the invention relates to polypeptides, in particular to purified polypeptides or recombinantly produced polypeptides.
  • the invention relates to full length polypeptides and also to corresponding ones
  • Fragments of these polypeptides for example certain motifs or domains.
  • This question elements can be of different lengths and include, for example, 5, 10, 25, 50, 100, 150, 200, 250 or 300 amino acids.
  • This invention also relates to fusion proteins comprising a polypeptide as described above.
  • the fusion protein can contain a further polypeptide portion which is not related to the ⁇ -tubulin (eg LexA, B42, glutathione-S-transferase, a His-Tag, a polypeptide with enzymatic activity like the alkaline phosphatase or an epitope day).
  • ⁇ -tubulin eg LexA, B42, glutathione-S-transferase, a His-Tag, a polypeptide with enzymatic activity like the alkaline phosphatase or an epitope day.
  • the invention also relates to a method for producing a polypeptide as described above in suitable prokaryotic or eukaryotic expression systems.
  • the expression can be permanent or transient in a respective cell line or host cell as described above.
  • Suitable prokaryotic expression systems are known host-vector systems such as bacteria (e.g. Streptomyces spp., Bacillus subtilis, Salmonella typhimurium, Serratia marcescens and especially Escherichia col ⁇ ).
  • Expression in a eukaryotic system is preferably carried out in the baculovirus system, particularly in a system which allows the introduction of post-translational modifications.
  • This invention also relates to the use of DNA as mentioned above for the detection of DNA from nematodes of the Strongylidae family, preferably the subfamily Cyathostominae, particularly preferably the genera Cyathostomum and Cylicocycle, very particularly preferably the species Cyathostomum coronatum and Cylicocyclus nassatus.
  • the invention relates to oligonucleotides as mentioned above which are complementary to DNA coding for ⁇ -tubulin or strands complementary thereto and can hybridize to this DNA. Preferably these oligonucleotides hybridize to the intron regions, i.e. the non-coding DNA sequences.
  • the invention relates to the use of these
  • Oligonucleotides or parts thereof as a) samples in Northern or Southern blot assays
  • PCR primer in a diagnostic method for the detection of the above-mentioned nematodes, the DNA of the relevant nematodes being specifically identified and amplified with the aid of the primer and the PCR technique.
  • the invention preferably relates to oligonucleotides consisting of or comprising one of the sequences according to SEQ ID NO. 12 to SEQ ID NO. 51st
  • the invention also relates to the use of DNA as mentioned above for the detection of DNA from nematodes of the Sfrongylidae family, preferably the subfamily of Cyathostominae, particularly preferably of the genera Cylicocycle, and Cyathostomum, very particularly preferably of the species Cylicocycle nassatus and
  • Cyathostomum coronatum which codes for ⁇ -tubulin or fragments thereof, which are resistant to benzimidazoles.
  • the invention relates to oligonucleotides as mentioned above which are complementary to DNAs which code for ⁇ -tubulin with a resistance to benzimidazoles or to the complementary strands of this DNA and which can hybridize specifically to this DNA.
  • the invention also relates to the use of these oligonucleotides or parts thereof as
  • PCR primer in a diagnostic method for the detection of the above-mentioned nematodes with a resistance to benzimidazoles, the DNA of the relevant nematodes being specifically identified and amplified with the aid of the primer and the PCR technique.
  • the invention preferably relates to oligonucleotides consisting of or comprising one of the sequences according to SEQ ID NO. 12 to SEQ LD NO. 51st
  • the invention also relates to a method for the detection of nematodes of the Strongylidae family, preferably the subfamily of Cyathostominae, particularly preferably of the genera Cylicocycle and Cyathostomum, very particularly preferably of the species Cylicocycle nassatus and Cyathostomum coronatum, oligonucleotides as described above on DNA sequences hybridize specifically, which originate from the organisms mentioned, and which can be amplified using the PCR technique.
  • the hybridization is preferably carried out in the non-coding regions of the ⁇ -tubulin gene (introns).
  • the detection of organisms as mentioned above can e.g. be done by
  • a) provides an oligonucleotide sample or primer which can hybridize to the abovementioned DNA coding for ⁇ -tubulin or to strands complementary thereto or to the 5 'or 3' flanking regions thereof,
  • the hybridization of the oligonucleotide or primer is detected (e.g. using the polymerase chain reaction),
  • the invention also relates to a method for the detection of nematodes of the Strongylidae family, preferably the subfamily of Cyathostominae, particularly preferably of the genera Cylicocycle and Cyathostomum, very particularly preferably of the species Cylicocycle nassatus and Cyathostomum coronatum, which are resistant to benzimidazoles, oligonucleotides such as described above
  • the hybridization is preferably carried out in the non-coding regions of the ⁇ -tubulin gene (infrons).
  • the detection of organisms as mentioned above can e.g. be done by
  • a) provides an oligonucleotide sample or primer which can hybridize to the abovementioned DNA coding for ⁇ -tubulin or to strands complementary thereto or to the 5'- or 3'-flanking regions thereof,
  • the hybridization of the oligonucleotide or primer is detected (e.g. using the polymerase chain reaction),
  • the invention also relates to a diagnostic test kit for the detection and identification of nematodes of the Sfrongylidae family, preferably the subfamily of Cyathostominae, particularly preferably of the genera Cylicocycle and Cyathostomum, very particularly preferably of the species Cylicocycle nassatus and Cyathostomum coronatum, which include oligonucleotides as above provides described, which can be used in methods for the detection of said species.
  • the present invention also provides oligonucleotides that are specific to sequences according to SEQ ID NO. 1, 3, 5, 7, 9 or 11, sequences complementary thereto, sequences with at least one point mutation in codon 200, or fragments of these sequences hybridize.
  • Oligonucleotides consisting of or comprising sequences according to SEQ LD NO are particularly preferred. 12 to SEQ ID NO. 51st
  • the invention also relates to a diagnostic test kit for the detection of nematodes of the Sfrongylidae family, preferably the subfamily of
  • Cyathostominae particularly preferably of the genera Cylicocycle and
  • Cyathostomum very particularly preferred of the species Cylicocyclus nassatus and
  • Cyathostomum coronatum with a resistance to benzimidazoles, which among other things provides oligonucleotides as described above, which can be used in methods for the detection of the species mentioned.
  • the present invention also provides oligonucleotides that are specific to sequences according to SEQ ID NO. 1, 3, 5, 7, 9 or 11, complementary to it
  • Oligonucleotides consisting of or comprising sequences according to SEQ ID NO are particularly preferred. 12 to SEQ ID NO. 51st
  • the invention also relates to a diagnostic test kit as described above, the oligonucleotides provided in this kit being provided with a detectable marker.
  • detectable markers can include enzymes, enzyme substrates, coenzymes, enzyme inhibitors, fluorescent markers, chromophores, luminescent markers and radioisotopes.
  • This invention also relates to antibodies which are specific to an epitope of a ⁇ -tubulin from nematodes of the Sfrongylidae family, preferably the
  • Cyathostominae particularly preferably of the genera Cylicocycle and Cyathostomum, very particularly preferably of the species Cylicocyclus nassatus and Cyathostomum coronatum react.
  • This invention also relates in particular to monoclonal antibodies which are specific to an epitope of a ⁇ -tubulin from nematodes of the Strongylidae family, preferably the Cyathostominae subfamily, particularly preferably the Cylicocycle and Cyathostomum genera, very particularly preferably the Cylicocyclus nassatus and Cyathostomum coronatum species, react.
  • This invention also relates to the use of the abovementioned antibodies as nematicides.
  • This invention also relates to the use of the abovementioned ⁇ -tubulin polypeptides or fragments thereof from nematodes of the family of
  • Strongylidae preferably the subfamily of Cyathostominae, particularly preferably of the genera Cylicocycle and Cyathostomum, very particularly preferably of the species Cylicocyclus nassatus and Cyathostomum coronatum, for the production of vaccines which contain at least one of the ⁇ -tubulin polypeptides or fragments thereof.
  • the vaccine is able to elicit an immune response that is specific for a ⁇ -tubulin described above.
  • the vaccine contains an antigenic determinant, for example a single determinant of a polypeptide with an amino acid sequence according to SEQ ID NO. 2, 4, 6, 8 or 10 or a polypeptide encoded by one of the aforementioned DNA or fragments thereof.
  • the invention also relates to a method for producing an immunogenic composition for immunizing mammals, consisting of at least one of the abovementioned ⁇ -tubulin polypeptides according to the invention or fragments thereof or of at least one of the abovementioned antibodies.
  • the invention also relates to the use of the expression vectors described above containing a nucleic acid coding for a ⁇ -tubulin according to the invention, preferably a sequence according to SEQ ID NO. 1, 3, 5, 7, 9 or 11, fragments thereof or sequences homologous thereto for the preparation of an immunogenic composition for administration into a host for activating a protective immune response in this host which is directed to ⁇ -tubulin from parasitic nematodes.
  • the invention also relates to an immunogenic composition
  • a vector comprising a nucleic acid coding for the ⁇ -tubulin according to the invention, preferably a sequence according to SEQ ID NO. 1, 3, 5, 7, 9 or 11, fragments thereof or sequences homologous thereto, and a promoter sequence which is functionally linked to said nucleotide sequence and which
  • ß-tubulin which triggers an immune response
  • carrier substance suitable for pharmaceutical purposes.
  • This invention also relates to a method for identifying substances which modulate the interaction of tubulin or the interaction of subunits of tubulin.
  • the method is based on the use of tubulin, preferably on tubulin from parasitic nematodes, particularly preferably on ß-tubulin from parastic nematodes of the order Strongylida, very particularly preferably on ß-tubulin from parasitic nematodes of the Sfrongylidae family, most preferably on ß- Tubulin from parastic nematodes of the subfamily of
  • Cyathostominae A particularly preferred group of in this process ß-tubulin used is ß-tubulin from parasitic nematodes of the genera Cylicocycle and Cyathostomum.
  • the invention relates to the identification of substances, e.g. small organic molecules that are able to modulate the interaction of tubulin protein molecules or their subunits with each other.
  • the invention preferably relates to the identification of compounds which inhibit the interaction.
  • the invention also relates to a method as described above, which is based on the fact that
  • the binding is detected by determining the ability of the tubulin protein molecules to interact with one another and
  • Presence of a test substance compared to the ability to interact with each other in the absence of a test substance.
  • the invention also relates to a method for identifying substances which modulate the ability of tubulin molecules to interact with one another.
  • the invention particularly preferably relates to a method which uses one of the above-described polypeptides which are encoded by the above-described DNAs or fragments thereof, in particular DNAs consisting of or comprising sequences according to SEQ ID NO. 1, 3, 5, 7, 9 or 11 and of sequences that have an identity of 85%, preferably Have 95% and code for ⁇ -tubulin, which has an amino acid sequence according to SEQ 2, 4, 6, 8 or 10.
  • the invention also relates to a method for identifying substances which modulate the ability of tubulin to interact with one another as described above, the method used being based on modulating the tubulin interaction in the presence of a test substance using a cell-based test system detect.
  • a preferred embodiment of such a test system is the so-called “two hybrid system” (US Pat. No. 5,283,317, Zervos et al. (1993) Cell 72, 223-232; WO 94/10300). This system is suitable for documenting or describing the interaction of two proteins in that the interaction leads to a detectable signal. Such a system can also be adapted to test systems with high throughput numbers.
  • the invention also relates to a method for identifying substances which modulate the ability of tubulin to interact with one another, the method used being based on detecting a modulation of the tubulin interaction in the presence of a test substance using a cell-free test system.
  • a particularly preferred embodiment of such a test system is the so-called "Scintillation Proximity Assay" (SPA)
  • microspheres a receptor bound to microspheres
  • beads e.g. B. a tubulin molecule with a ligand, the microspheres or beads being provided with a scintillating molecule.
  • a signal is detected when the receptor-ligand complex disintegrates.
  • the invention also relates to substances not yet described, which are identified with the aid of the methods described above and are suitable for modulating, preferably inhibiting, the interaction of tubulin molecules.
  • the invention also relates to the use of substances which have not yet been described and which have been identified using one of the methods described above, for the preparation of an agent which is used for the prophylactic or therapeutic treatment of animals or humans which may or may be infected by nematodes ,
  • the agents according to the invention contain at least one of the substances identified by one of the methods described above and can be administered nasally, dermally, parenterally or enterally.
  • fragments in relation to proteins and DNA describes parts of the SEQ LD NO. 1 to 11 described nucleic acids or amino acid sequences, complementary sequences or 85%, preferably 95% identical sequences.
  • the fragments of the DNA and polypeptide sequences comprise at least 5 nucleotides or amino acids, but can also contain up to 447 amino acids or up to 1343 nucleotides, or up to 2565 nucleotides in the case of the sequence according to SEQ ID NO. 11 include.
  • homology refers to sequence similarities between two peptides or between two nucleic acid molecules. Homology can be determined by comparing one position in each sequence. Is a position in the compared sequence of the same
  • a "non-homologous" sequence has an identity of less than 40%, but preferably less than 25% identity.
  • the term "homology” means in particular that DNA segments of at least 15 base pairs in length or complementary to the DNA in at least 85%, preferably 95% of the nucleotides match the corresponding DNA. Homology can be determined, inter alia, with the aid of computer programs such as the GCG program (Devereux et al. (1983), Nucleic Acids Res. 12, 387-395).
  • a "homology” also exists if a DNA segment can hybridize to the releasing DNA strand or its complementary strand.
  • hybridize or “hybridization” describes the process in which a single-stranded nucleic acid molecule with a complementary DNA strand forms a base pair, the ability of a single-stranded nucleic acid molecule depending on the stringency of the hybridization conditions.
  • stringency refers to the hybridization conditions. "High stringency” is given when a base pairing is difficult. “Low stringency” is given when a base pairing is facilitated.
  • Pyrimidine nucleotides to form base pairs with one another via hydrogen bonds.
  • Complementary base pairs include Guanine and cytosine, adenine and thymine and adenine and uracil.
  • the person skilled in the art is aware that, owing to the degenerate genetic code (ie 64 codons coding for 20 amino acids), numerous "silent" substitutions of nucleotide base pairs can be introduced into the sequence set out for this purpose without changing the identity of the protein products encoded by them. All such substitutions are intended to be included within the scope of the invention.
  • the term "specifically hybridize” refers to the ability of a nucleic acid molecule of the present invention to have at least about 6, 12, 20, 30, 50, 100, 150, 200, 300, 350, 400 or 440 consecutive nucleotides of one of the hybridize ⁇ -tubulin genes described above, preferably to one of the sequences according to SEQ LD NO.
  • Plasmid refers to an extrachromosomal genetic element.
  • the original plasmids used for the present invention are either commercially available, freely accessible or can be derived from such plasmids by known methods.
  • vector describes a DNA element that is used to introduce exogenous DNA into host cells.
  • a vector contains a nucleotide sequence that encodes one or more polypeptides.
  • Vectors that are capable of directing the expression of the genes that contain them are referred to as "expression vectors”.
  • the term “gene” refers to a nucleic acid containing an open reading frame which codes for one of the ⁇ -tubulin polypeptides described above. Both exon and possibly infron sequences are included.
  • the term “interact” or “interaction” describes detectable interactions between molecules.
  • the term “bond” is included.
  • modulate refers to both stimulation and suppression or inhibition of a biochemical process. In the context of the present invention, “modulation” means an inhibition or suppression of the interaction between tubulin polypeptides or fragments or subunits thereof, or a stimulation of this interaction, which can manifest itself, for example, in an irreversible binding of tubulin polypeptides to one another.
  • nucleic acid refers to polynucleotides such as deoxyribonucleic acids (DNA) or, if appropriate, to ribonucleic acids (RNA).
  • DNA deoxyribonucleic acids
  • RNA ribonucleic acids
  • the term also includes, in an equivalent manner, analogs of RNA or DNA derived from
  • Nucleotide analogs are produced, as well as single-stranded (“sense” or “antisense”) and double-stranded polynucleotides if applicable.
  • promoter refers to DNA sequences that regulate the expression of a particular DNA that are operably linked to the promoter.
  • tissue-specific promoters i.e. Promoters that control the expression of the specific DNA only in certain cells (e.g. cells of a certain tissue). Also included are “tissue-unspecific” promoters and promoters that lead to constitutive expression or are inducible.
  • protein protein
  • polypeptide peptide
  • a “fusion protein” is a fusion of a first amino acid sequence coding for one of the ⁇ -tubulin polypeptides described above with a second amino acid sequence which has no commonality or basic homology to the tubulin sequence.
  • the second amino acid sequence can originate from the same organism as the first, or alternatively originate from another organism (intergenic).
  • a fusion protein can use the formula
  • X-tubulin-Y are reproduced, "tubulin” for any of the above polypeptides described, and X and Y stand for a polypeptide that is not related to a tubulin amino acid sequence. X or Y can each be absent independently.
  • cell or "host cell” can be used in the context of the present
  • Registration can be used in the same sense. It is understood that these terms refer not only to a single cell, but also to the descendants of such a cell. Due to certain modifications in the course of subsequent generations (e.g. mutations), such offspring may not be identical to the stem cell, but are included in the present invention.
  • genomic describes such sequences of the described, preferably genomic, DNA, which are transcribed, but then removed from the transcript by so-called “splicing”, the adjacent sequences (exons) being linked.
  • one aspect of the invention relates to nucleic acids from nematodes of the Sfrongylidae family, particularly the subfamily of Cyathostominae, very particularly to the genera Cyathostomum and Cylicocycle, especially the species Cylicocyclus nassatus and Cyathostomum coronatum, which are suitable for ⁇ -tubulin Encoding polypeptides, or fragments thereof or nucleic acids homologous thereto, which contain the in SEQ ID NO. 1, 3, 5, 7, 9 and 11 are 85%, preferably 95% homologous and for a ⁇ -tubulin according to one of the sequences according to SEQ ID NO. Encode 2, 4, 6, 8 or 10 or fragments thereof.
  • SEQ ID NO. 3 shows the degenerate sequence of the nucleic acid from ⁇ -tubulin from Cylicocycle nassatus, where "r” stands for a purine (guanine or adenine), "y” for a pyrimidine (thymine or uracil or cytosine) and "w” for an adenine or a thymine or an uracil.
  • SEQ ID NO. 3 thus comprises a series of sequences that can be present in organisms of the species Cylicocyclus nassatus.
  • the sequences according to SEQ ED NO. 5, 7 and 11 show three defined sequences coding for ⁇ -tubulin, the exemplary and preferred embodiments of DNA according to SEQ ID NO. 3 are.
  • oligonucleotides which optionally code for ⁇ -tubulin polypentides which have a length of at least 2, 5, 10, 25, 50, 100, 150, 200, 250, 300, 350 or 400 amino acids.
  • Such oligonucleotides can serve as primers or antisense molecules (ie as non-coding nucleic acids) and comprise at least about 6, 12, 24, 30, 60, 100, 120, 150 or 210 base pairs, while coding nucleic acids about 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200 or 1300 base pairs.
  • the invention also describes those oligonucleotides that hybridize specifically under stringent conditions to nucleic acids derived from one of the
  • Sequences according to SEQ ID NO. 1, 3, 5, 7, 9 or 11 can be played.
  • stringent conditions are e.g. 6 x sodium chloride / sodium citrate (SSC) at about 45 ° C, followed by a washing step with 2 x SSC at 50 ° C, and are familiar to the person skilled in the art (see, for example, Current protocols in Molecular Biology, John Wiley & Sons, NY (1989) , 6.3.1-6.3.6). So the salt concentrations in
  • Wash step selected so that the stringency is lower (2 x SSC, 50 ° C) or higher (0.2 x SSC, 50 ° C).
  • the temperature during the washing step can also be varied, from conditions for low stringency (e.g. approx. 22 ° C) to conditions for high stringency (e.g. approx. 65 ° C). Both salt concentration and temperature can be varied and coordinated.
  • oligonucleotides used as primers or for hybridization to identify and characterize one, e.g. genomic, DNA are in SEQ ID NO. 12-51.
  • the infrons are the sequences located between the coding exons.
  • the described primers or hybridization probes contain a labeled group which enables the detection of the oligonucleotides, e.g. Radioisotopes, fluorescent groups,
  • oligonucleotides can be used in diagnostic test kits to determine the origin (i.e. the organism) of an existing DNA.
  • the oligonucleotides are characterized by their specific hybridization with the
  • SEQ ID NO. 1, 3, 5, 7, 9 and 11 called DNAs their fragments, homologous sequences and complementary sequences suitable for recognizing defined sequences. They thus also enable the recognition and identification of sequences coding for ⁇ -tubulin which, owing to one or more point mutations in codon 200, lead to the expression of benzimidazole-resistant ⁇ -tubulin.
  • Embodiments 12 to 51 described are thus suitable for identifying the frequently occurring nematode species of the subfamily of the Cyathostominae, as well as for recognizing existing resistance to benzimidazoles.
  • the oligonucleotides according to the present invention can be produced using standard methods which are known to the person skilled in the art, for example by de novo DNA synthesis.
  • the nucleic acids mentioned here can be present in complete cells, in cell lysates, in partially purified or biologically pure form, ie when other cell components or chemical precursors and by-products have been separated in the case of chemical synthesis of the DNA.
  • Nucleic acids encoding ⁇ -tubulin can be obtained starting from mRNA which is present in a number of eukaryotic cells. It is also possible to obtain the DNA according to the invention starting from genomic DNA from the relieving nematode cells (see also the following examples).
  • a gene coding for ⁇ -tubulin can e.g. can be obtained from a cDNA or a genomic DNA library.
  • cDNA can be obtained by looking at the total mRNA of a cell, e.g. a nematode cell, isolated. Based on the mRNA, double-ended cDNA can then be produced and inserted into a suitable plasmid or a suitable vector.
  • the DNA according to the invention can also be obtained by amplification with
  • the present invention also encompasses expression vectors which contain one of the nucleic acid sequences according to the invention, which are functionally linked to a frictional regulatory sequence.
  • “Functionally linked” means that the nucleic acid sequence is linked to the regulatory sequence in such a way that the expression of the protein encoded by the nucleic acid sequence can be controlled.
  • "Transcription regulatory sequences” include e.g. B. promoters, enhancers and other control elements.
  • the expression vectors contain e.g. B. encoding a gene for an inventive ⁇ -tubulin or fragments thereof. These vectors can be used to be introduced into cells, where the corresponding polypeptides or fusion proteins are then formed. Matching pro Motors for expression of the protein according to the invention in E.
  • coli include natural hybrid or bacteriophage promoters. These are preferably promoters from the group of phage ⁇ promoters, omp or synthetic promoters (see also WO 98/15625, DE 3 430 683, EP 0 173 149). Suitable vectors are commercially available, for example the expression vectors of the pET series
  • the expression vectors can then be transformed, for example, into DE3-lysogenic E. coli strains, for example BL21 (DE3), HM S 174 (DE3) or AD494 (DE3).
  • the present invention also encompasses cells that contain the nucleic acid sequences of the invention (e.g., inserted into a vector or into the genome). These host cells can be prokaryotic or eukaryotic.
  • Suitable prokaryotic expression systems are e.g. bacterial systems such as Streptomyces spp., Bacillus subtilis, Salmonella typhimurium, Serratia marcescens and preferably E. coli.
  • a preferred eukaryotic expression system is the baculovirus system, particularly preferably that which allows post-translational modifications.
  • eukaryotic expression systems e.g. yeast, insect cells
  • yeast e.g. yeast, insect cells
  • the present invention also comprises ⁇ -tubulin polypeptides which are derived from the DNAs according to the invention, preferably the DNA sequences according to SEQ ID NO. 1,
  • polypeptides are encoded, from fragments of the same or from homologous DNA sequences as described above.
  • Preferred embodiments of these ⁇ -tubulin polypeptides are in the sequences according to SEQ LD NO. 2, 4, 6, 8 and 10.
  • the described polypeptides are purified polypeptides which are free from contaminating proteins of those cells in which the polypeptides according to the invention were produced.
  • polypeptides described are full-length proteins or fragments, motifs or domains thereof that have lengths of at least 5, 10, 25,
  • Polypeptide fragments can be obtained and selected by testing polypeptides derived from nucleic acid fragments from the sequences according to SEQ ID NO. 1, 3, 5, 7, 9 and 11 can be encoded.
  • Polypeptide fragments can also be chemically synthesized in a known manner.
  • the invention also encompasses polypeptides derived from the degenerate sequence according to SEQ ID NO. 3 can be encoded.
  • the different possible bases at defined positions in the DNA sequence result in different polypeptides with the amino acid encoded by the respective codon.
  • the DNA according to SEQ ID NO. 3 encoded polypeptides are in SEQ LD NO. 4, the variable amino acids being identified by "Xaa”.
  • polypeptides are in SEQ ID NO. 2, 4, 6, 8 and
  • the present invention also includes methods for producing the polypeptides of the invention.
  • polypeptides of the present invention can be obtained in various ways, e.g. through chemical methods like the solid phase method. The use of recombinant methods is recommended to obtain larger amounts of protein.
  • the expression vectors can be transformed into ⁇ DE3-lysogenic E. co / z ' strains, for example BL21 (DE3), HM S174 (DE3) or AD494 (DE3). After the cells have grown under standard conditions familiar to the person skilled in the art, expression is induced with IPTG. After induction of the cells for 3 to 24
  • Homologs or fragments of the polypeptides according to the invention can be generated by mutagenesis, e.g. by directed (point) mutagenesis, or by deletions.
  • polypeptides according to the invention can also be chemically modified, for example with glycosyl groups, lipids, phosphates, acetyl groups or the like Groups.
  • Covalent derivatives can be obtained by linking the modifying group to functional groups of the amino acid side chains or the N-terminus or C-terminus of the polypeptide.
  • polypeptides according to the invention can also be present as part of a fusion protein. Such fusion proteins are fully encompassed by the present invention. Fusion proteins can be useful under conditions where it is desirable to obtain an immunogenic fragment of ⁇ -tubulin (see, e.g., EP 0259 149; Schlienger et al. (1992) J. Virol. 66, 2). Fusion proteins facilitate expression of a polypeptide in certain circumstances.
  • the polypeptides according to the invention can be produced as glutathione-S-transferase (GST) fusion proteins.
  • GST fusion proteins enable the polypeptide to be easily purified (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al.
  • Fusion proteins can contain, for example, a "leader" sequence which the Purification serves, for example, a poly-His sequence at the N-terminus (but also at the C-terminus) of the protein allows its purification by means of chromatography on a Ni 2+ -NTA column (see, for example, Hachuli et al. (1987) J. Chromatography 411, 177).
  • Another aspect of the present invention relates to antibodies which react specifically with the ⁇ -tubulin polypeptides according to the invention.
  • anti-protein or anti-peptide antisera or monoclonal antibodies can be produced according to standard protocols (see, for example, Antibodies: A. Laboratory Manual ed. By Harlow and Lane (Cold Spring Harbor Press, 1988)).
  • Mammals such as mice, hamsters or rabbits can be immunized with an immunogenic form or an immunogenic portion of the polypeptide according to the invention, ie with a polypeptide which is able to elicit an antibody response (see also "fusion proteins" above).
  • an immunogenic portion of the ⁇ -tubulin can be administered in the presence of an adjuvant.
  • the course of the immunization can be monitored by checking the antibody titer in plasma or serum, e.g. by common ELISA or other immunoassays.
  • the antibodies according to the invention are immunospecific for an antigenic determinant of a ⁇ -tubulin polypeptide according to the invention, e.g. a polypeptide according to SEQ LD NO. 2, 4, 6, 8 or 10 or such polypeptides derived from DNAs according to SEQ ID NO. 1, 3, 5, 7, 9 or 11 or thus 85% identical sequences, preferably 95% identical sequences.
  • a polypeptide according to SEQ LD NO. 2, 4, 6, 8 or 10 or such polypeptides derived from DNAs according to SEQ ID NO. 1, 3, 5, 7, 9 or 11 or thus 85% identical sequences, preferably 95% identical sequences.
  • polyclonal anti-ß-tubulin antibodies can be isolated from the serum.
  • antibody-producing cells lymphocytes
  • Animal can be obtained and according to known methods with immortal cells such as Myeloma cells are fused to obtain hybridoma cells (see e.g. Koehler and Milstein (1975) Nature 256, 495-497; Kozbar et al. (1983) Immunology Today 4, 72; Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 77-96).
  • immortal cells such as Myeloma cells are fused to obtain hybridoma cells (see e.g. Koehler and Milstein (1975) Nature 256, 495-497; Kozbar et al. (1983) Immunology Today 4, 72; Cole et al. (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 77-96).
  • antibodies are also intended to include fragments of antibodies which react specifically with ⁇ -tubulin according to the invention. Antibodies can be fragmented using conventional techniques and the fragments checked.
  • a preferred embodiment relates to antibodies as described above which carry a detectable marker (e.g. radioisotopes, fluorescent groups, enzymes or enzyme cofactors).
  • a detectable marker e.g. radioisotopes, fluorescent groups, enzymes or enzyme cofactors.
  • Antibodies that bind specifically to ⁇ -tubulin polypeptides according to the invention can also be used for immunohistochemical staining of tissue samples in order to detect the expression of a specific ⁇ -tubulin.
  • the anti-ß tubulin antibodies can also be used for diagnostic purposes, e.g. be used for immunoprecipitation or for immuno-blotting.
  • the present invention also provides nucleic acid molecules that can be used for diagnostic purposes.
  • nucleic acid molecules as described above, the fragments of the under SEQ ID NO. 1, 3, 5, 7, 9 or 11 described or complementary DNA sequences.
  • Oligonucleotides according to SEQ ID NO. Provided 12 to 51, which are able to hybridize to Sens or antisense sequences coding for ß-tubulin, and to infrared sequence sections, which are exemplified in SEQ ID NO. 11 are described.
  • the nucleic acid of a cell is made accessible for hybridization, the DNA sample is brought into contact with the oligonucleotides, and the hybridization of the sample with the oligonucleotide is detected.
  • a method is made available which makes it possible, by specific hybridization of the oligonucleotides according to the invention to a DNA sample, preferably with the aid of those oligonucleotides which hybridize to the infrared regions of the DNA coding for ⁇ -tubulin, between different species to distinguish between small strongyles and / or other nematode species.
  • the oligonucleotides according to the invention allow the identification of resistance in small (Cyathostaminae), e.g. in horses, especially resistance of the species Cylicocyclus nassatus, Cyathostomum coronatum and Cyathostomum catinatum.
  • small Cyathostaminae
  • Ask point mutation in the DNA coding for it according to the invention which can be detected by PCR, such as. B. described in an analogous manner in Elard et al. (1998) PCR diagnosis of benzimidazole-susceptibility or -resistance in natural populations of the small ruminant parasite, Teladorsagia circumcincta. Veterinary Parasitology 80, 231-237.
  • the described method is particularly helpful for assessing possible treatment strategies in humans and animals infected with nematodes, e.g. Horses, sheep, pigs, goats, camels, buffaloes, donkeys, rabbits, roe deer, fur animals, birds (e.g. chickens, turkeys, ducks), fresh and saltwater fish (e.g.
  • nematodes e.g. Horses, sheep, pigs, goats, camels, buffaloes, donkeys, rabbits, roe deer, fur animals, birds (e.g. chickens, turkeys, ducks), fresh and saltwater fish (e.g.
  • Trout carp. It enables the identification and differentiation of the parasitic nematodes and the detection of resistant populations thereof, and prevents treatment with ineffective nematicides.
  • Test kits are made available that include at least one of the above Contain nucleic acid molecules or an antibody as described above, which is prepared ready for use.
  • the invention relates to a method in which novel, specific anthelmintic substances can be identified with the help of tubulin or fragments thereof.
  • ⁇ -tubulin polypeptides according to the present invention are used for this.
  • the method can also be carried out with tubulin from other species than those mentioned here. Methods that use ß-tubulin polypeptides other than the invention are fully encompassed by the present invention.
  • ⁇ -Tubulin polypeptides according to SEQ ID NO. are particularly preferred for the method mentioned. 2, 4, 6, 8 or 10 used.
  • recombinant ⁇ -tubulin polypeptides from frequently occurring parasitic nematodes are thus additionally made available. These can be used in various test systems to identify new inhibitors of the tubulin interaction or the interaction of the tubulin subunits.
  • test systems aimed at testing compounds and natural extracts are designed for high throughput numbers in order to maximize the number of substances tested in a given period of time.
  • Test systems that are based on cell-free work require purified or semi-purified protein. They are suitable for a "first" test, which primarily aims to detect a possible influence of a substance on the target protein. Effects such as cell toxicity are usually ignored in these in vitro systems.
  • the test systems check both inhibitory or suppressive effects of the substances as well as stimulatory effects. The effectiveness of a substance can be checked using concentration-dependent test series. Confusion approaches without test substances can be used to evaluate the effects.
  • SPA Scintillation Proximity Assay
  • Photon emits The test conditions are optimized so that only those particles originating from the ligand lead to a signal which originate from a ligand bound to the receptor or the tubulin.
  • tubulin is bound to the beads, either together or without interacting or binding test substances.
  • ⁇ - or ⁇ -tubulin subunits could be used.
  • a radiolabelled ligand could e.g. B. be a labeled benzimidazole or another labeled ß-tubulin molecule. If the ligand binds to the immobilized tubulin, this ligand would have to inhibit or abolish an existing interaction between immobilized and free tubulin in order to bind itself in the area of the contact area. Successful binding to the immobilized tubulin can then be detected using a flash of light. Accordingly, an existing complex between an immobilized and a free, labeled tubulin is destroyed by the binding of a test substance, which leads to a drop in the detected Light flash intensity leads.
  • the test system then corresponds to a complementary inhibition system.
  • the ⁇ -tubulin available through the present invention enables the development of test systems based on cells for the identification of substances which inhibit the tubulin interaction.
  • test system An example of such a test system is the so-called "two hybrid system".
  • reaction trap It is a genetic selection of interacting proteins in yeast (see e.g. Gyuris et al. (1993) Cdi 1, a human Gl and S phase protein phosphatase that associates with Cdk 2. Cell 75, 791-803).
  • the test system is designed to detect and describe the interaction of two proteins in that an interaction that has taken place leads to a detectable signal.
  • test system can also be adapted to the testing of large numbers of test substances in a given period.
  • the system is based on the construction of two vectors, the "bait" and the "prey” vector.
  • a gene coding for tubulin preferably a gene coding for a ⁇ -tubulin according to the invention, is cloned into the bait vector and then expressed as a fusion protein with the LexA protein, a DNA-binding protein.
  • a second gene, coding for tubulin, preferably for a ⁇ -tubulin according to the invention, is cloned into the Prey vector, where it is expressed as a fusion protein with the B42-Prey protein.
  • Both vectors are in a Saccharomyces cerevisiae-Wi ⁇ t, which contains copies of LexA-binding DNA on the 5 'side of a lacZ or HIS 3 reporter gene. If there is an interaction between the two tubulin (fusion) proteins, the transcription of the is activated
  • Reporter gene The presence of a test substance leads to inhibition or Disruption of the tubulin interaction, the two tubulin (fusion) proteins can no longer interact, the product of the reporter gene is no longer produced.
  • tubulin especially the ß-tubulin according to the invention or fragments thereof, and the methods described above, it is possible to identify new and specific antiparasitic compounds.
  • the compounds are active against all developmental stages of normal, sensitive strains and also resistant strains. Treatment with agents containing one or more of these compounds can prevent or treat both economic losses in farm animals and diseases in humans and animals.
  • the following parasites are of particular interest as targets of the active compounds found:
  • Enoplida e.g. Trichuris spp., Capilla ⁇ a spp., Trichomosoides spp., Trichinella spp.
  • Rhabditia e.g. Micronema spp., Strongyloides spp.
  • Strongylida e.g. Strongylus spp., Triodontophorus spp., Oesophagodontus spp., Trichonema spp., Gyalocephalus spp., Cylindropharynx spp., Poteriostomum spp., Cyclococercus spp., Cylicostephanus spp., Oesophagostomurus spp.,.
  • Ancylostoma spp. Uncinaria spp., Bunostomum spp., Globocephalus spp., Syngamus spp., Cyathostomum spp., Cylicocyclus spp., Neostrongylus spp., Cystocaulus spp., Pneumostrongylus spp., Spicocaulus spp., Spicocaulus spp.
  • Par elaphostrongylus spp. Crenosoma spp., Paracrenosoma spp., Angiostrongylus spp., Aelurostrongylus spp., Filaroides spp., Parafilaroides spp., Tricho-strongylus spp., Haemonchus spp., Ostertagia spp., Marshall Cooperia spp., Nematodirus spp., Hyostrongylus spp., Obeliscoides spp., Amidostomum spp.,
  • Oxyurida e.g. Oxyuris spp., Enterobius spp., Passalurus spp., Syphacia spp., Spz-culuris spp., Heterakis spp. Ascaridia, e.g. Ascaris spp., Toxascaris spp., Toxocara spp., Parascaris spp., Anisaki spp., Ascaridia spp.
  • Spirurida e.g. Gnathostoma spp., Physaloptera spp., Thelazia spp., Gongylonema spp., Habronema spp., Parabronema spp., Draschia spp., Dracunculus spp.
  • Filariida e.g. Stephanoßlaria spp., Parafilaria spp., Setaria spp., Zo ⁇ spp., Diroßlaria spp., Litomosoides spp., Brugia spp., Wuchereria spp., Onchocerca spp.
  • Gigantorhynchida e.g. Filicollis spp., Moniliformis spp., Macracanthorhynchus spp., Prosthenorchis spp.
  • Trypanosomatidae e.g. Trypanosoma b. brucei, T. b. gambiense, T b. rhodesiense, r. congolense, T. cruzi, T. evansi, T. equinum, T. lewisi, T. percae, T. simiae, T. vivax, Leishmania brasiliensis, L. donovani, L. tropica
  • Trichomonadidae e.g. Giardia lambilia, G. canis.
  • Hartmanellidae e.g. Acanthamoeba sp., Hartmanella spp. Apicomplexa (Sporozoa), e.g. Bucket ia acervulina, E. adenoides, E. alabahmensis,
  • Plasmodiidae e.g. Plasmodium berghei, P. falciparum, P. malariae, P. ovale, P. vivax, P. spec.
  • Piroplasmea e.g. Babesia argentina, B. bovis, B. canis, B. spec, Theileria parva, T. spec.
  • Myxospora and Microspora e.g. Glugea spec. and Nosema spec, as well as Pneumocystis carinii, Ciliophora (Ciliata), e.g. Balantidium coli, Ichthiophthirius spec., Trichondina spec. or Epistylis spec.
  • the compounds and agents found are also effective against protozoa of insects, such as those of the Microsporidia strain, especially those of the order Nosema, especially those of the species Nosema apis, which are parasites of the honeybee.
  • mRNA was obtained using the Quick Prep® Micro mRNA Kit (Pharmacia Biotech, Freiburg, Germany) from C. nassatus-Wü ⁇ mem and from C. coronatum and Cc ⁇ t ⁇ tam worms with the Dynal® mRNA Direct Kit (Dynal, Hamburg, Germany) won.
  • the worms were isolated from the colon of horses and differentiated microscopically according to the characteristic structure of the head and tail (see RS Lichtenfeld (1975), Helminths of domestic equids. Proceedings of the Helminthological Society, Washington, 42 (Special issue), 1-92 ).
  • the cDNA was synthesized using the "reverse transcription system"
  • Genomic DNA was obtained from 4 to 40 adult worms using the QIA Amp-Tissue Kit (Qiagen, Hilden, Germany). The worms were digested with Proteinase K for 2 hours at 55 ° C and the genomic DNA extracted with "Spin Columns".
  • amplification of full-length ⁇ -tubulin sequences or fragments can e.g. with AmpliTaq Gold TM polymerase (Perkin Elmer, Foster City, California, USA).
  • An amplification of the ⁇ -tubulin sequences according to SEQ ID NO. 1, 3, 5, 7, 9 or 11 or fragments thereof can be prepared using the primers according to SEQ LD NO. 12 - 51.
  • the sequences according to SEQ ID NO. are particularly suitable for the amplification of the C. catinatum cDNA. 40 and 42.
  • the amplification of the C. nassatus cDNA and the genomic DNA of all species according to the present invention was carried out in a total volume of 50 ⁇ l, containing 5 ⁇ l 10 ⁇ buffer, 2.5 ⁇ l MgCl 2 (25 mM), 2 ⁇ l dNTP mix (2mM per NTP), 1 ⁇ l of each specific primer (SEQ ID NO. 12 - 47) (50 p mol / ⁇ l), 0.5 ⁇ l (2.5 U)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un ADN codant pour la β-tubuline de nématodes de la famille des strongylidés, le polypeptide codé par cet ADN, l'utilisation de cet ADN pour diagnostiquer la résistance anthelmintiques des nématodes concernés et pour identifier l'espèce des nématodes parasites, l'utilisation de la β-tubuline comme constituant d'un vaccin et un procédé d'identification de composés anthelmintiques ou antibiotiques.
EP00956159A 1999-07-09 2000-06-30 ADN CODANT POUR LA $g(b)-TUBULINE ET LEUR UTILISATION Withdrawn EP1208199A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19931883 1999-07-09
DE19931883A DE19931883A1 (de) 1999-07-09 1999-07-09 DNA kodierend für Beta-Tubulin und deren Verwendung
PCT/EP2000/006104 WO2001004281A2 (fr) 1999-07-09 2000-06-30 ADN CODANT POUR LA β-TUBULINE ET LEUR UTILISATION

Publications (1)

Publication Number Publication Date
EP1208199A2 true EP1208199A2 (fr) 2002-05-29

Family

ID=7914118

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00956159A Withdrawn EP1208199A2 (fr) 1999-07-09 2000-06-30 ADN CODANT POUR LA $g(b)-TUBULINE ET LEUR UTILISATION

Country Status (9)

Country Link
EP (1) EP1208199A2 (fr)
JP (1) JP2003504051A (fr)
CN (1) CN1382216A (fr)
AU (1) AU6821500A (fr)
BR (1) BR0012274A (fr)
CA (1) CA2378407A1 (fr)
DE (1) DE19931883A1 (fr)
HK (1) HK1050026A1 (fr)
WO (1) WO2001004281A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145314A1 (fr) * 2008-05-29 2009-12-03 花王株式会社 Procédé de détection de paecilomyces variotii
CN102492775B (zh) * 2011-12-15 2013-09-11 童永清 抗微管化疗药物基因TUBB3 mRNA表达量快速检测试剂盒
CN115282267A (zh) * 2022-04-29 2022-11-04 浙江师范大学 一种多子小瓜虫β-微管蛋白核酸疫苗的制备方法
CN121243347A (zh) * 2025-12-03 2026-01-02 山东中医药大学附属医院 一种多肽在制备糖尿病肾病缓解剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001832A (nl) * 1990-08-16 1992-03-16 Rijksuniversiteit Specifieke sequenties van dna van een nematode die toegepast kunnen worden bij de diagnostiek van infektie met de nematode.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0104281A2 *

Also Published As

Publication number Publication date
CN1382216A (zh) 2002-11-27
WO2001004281A3 (fr) 2001-07-12
DE19931883A1 (de) 2001-01-11
JP2003504051A (ja) 2003-02-04
CA2378407A1 (fr) 2001-01-18
WO2001004281A2 (fr) 2001-01-18
HK1050026A1 (zh) 2003-06-06
AU6821500A (en) 2001-01-30
BR0012274A (pt) 2002-03-12

Similar Documents

Publication Publication Date Title
Blackhall et al. Selection at a γ-aminobutyric acid receptor gene in Haemonchus contortus resistant to avermectins/milbemycins
DE69635455T2 (de) Dna kodierend für glutaminsäure-gesteuerte chloridkanäle
EP1841788A1 (fr) Nouvelle toxine provenant d'un serpent
DE69830422T2 (de) Zyklische nukleotid-vermittelte ionenkanal verbindungen aus hirn und herz sowie deren verwendungen
US6403308B1 (en) Methods for detecting and reversing resistance to macrocyclic lactone compounds
JP3623798B2 (ja) グルタメートゲーテッド塩素イオンチャンネルをコードするｄｎａ
DE60031241T2 (de) Kaliumkanäle und für diese kaliumkanäle kodierende gene
EP1208199A2 (fr) ADN CODANT POUR LA $g(b)-TUBULINE ET LEUR UTILISATION
DE69631516T2 (de) Familie von Kaliumkanälen von Säugetieren, deren Klonierung und Anwendung für Drogenscreening
EP1317562A2 (fr) Systemes de test bases sur des transmembrane recepteurs de helminths et leur utilisation pour l'identification et la caracterisation de composes
US20050037436A1 (en) Test systems and the use thereof for identifying and characterizing compounds
DE60029108T2 (de) Von cycklischem gmp-abhängige proteinkinase als chemotherapeutisches ziel für gegen protozoen gerichtete agenzien
DE60123401T2 (de) Gen 763 aus dem pflanzpathogenen pilz magnoporthe grisea und dessen verwendung zum nachweis neuer fungizide
Blackhall Genetic variation and multiple mechanisms of anthelmintic resistance in Haemonchus contortus
DE10053785A1 (de) Testsysteme und deren Verwendung zur Identifizierung und Charakterisierung von Verbindungen
Galazzo A comparison of laboratory and field resistance to macrocyclic lactones in Haemonchus contortus
MXPA99009998A (en) Methods for detecting and reversing resistance to macrocyclic lactone compounds
Njue Mechanisms of anthelmintic resistance in Cooperia oncophora, a nematode parasite of cattle
Amliwala Molecular and genetic determinants of the inhibitory action of emodepside on C. elegans muscle
von Samson-Himmelstjerna Anthelmintic resistance in helminths of horses and ruminants: Recent molecular research data
Pietrantonio Cloning and immunolocalization of a 17 kDa protein implicated in V-ATPase mediated proton transport and gap junctional communication in the tobacco budworm, Heliothis virescens
CONTORTUS Institute of Parasitology
Law Ectopic expression in remodeled C. elegans: a platform for target identification, anthelmintic screening and receptor deorphanization
DE19704024A1 (de) Proteine, dafür kodierende DNA-Sequenzen, dagegen spezifische Antikörper und ihre Verwendung zum Auffinden nematizider Wirkstoffe
EP1499639A1 (fr) Nouvelles sequences d'acides nucleiques et proteines de tumeurs et neoplasies de la glande thyroide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER HEALTHCARE AG

17Q First examination report despatched

Effective date: 20060825

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070105